Base de dados : MEDLINE
Pesquisa : D27.505.954.944 [Categoria DeCS]
Referências encontradas : 433 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 44 ir para página                         

  1 / 433 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29351556
[Au] Autor:Li J; Tian Y; Guo S; Gu H; Yuan Q; Xie X
[Ad] Endereço:Chinese Academy of Sciences Key Laboratory of Receptor Research, National Center for Drug Screening, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
[Ti] Título:Testosterone-induced benign prostatic hyperplasia rat and dog as facile models to assess drugs targeting lower urinary tract symptoms.
[So] Source:PLoS One;13(1):e0191469, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Benign prostatic hyperplasia (BPH) is an age-related disease, affecting a majority of elderly men worldwide. Medical management of BPH is an alternative to surgical treatment of this disease. Currently, α1-adrenergic receptor (α1-AR) antagonists are among the first line drugs to treat BPH by reducing the tension of urinary track and thus the obstructive symptoms in voiding. In drug development, old male dogs with spontaneous BPH are considered the golden standard of the animal models. However, old dogs (>6 years) are expensive and not all old dogs develop BPH. So it is necessary to develop more accessible animal models for drug efficacy evaluation. Here we describe the development of testosterone-induced BPH models in both rats and young adult dogs and their applications in the in vivo evaluation of α1-AR antagonist. The BPH rats and dogs induced by chronic testosterone treatment have significantly increased micturition frequency and reduced mean voided volume, very similar to the clinical symptoms of BPH patients. Silodosin, an α1-AR antagonist, significantly reduces the urinary frequency and increases the voided volume in BPH model animals in a dose-dependent manner. The results demonstrate that testosterone-induced BPH rat and dog models might provide a more efficient way to evaluate micturition behavior in anti-BPH drug studies.
[Mh] Termos MeSH primário: Sintomas do Trato Urinário Inferior/tratamento farmacológico
Hiperplasia Prostática/induzido quimicamente
Testosterona/toxicidade
[Mh] Termos MeSH secundário: Antagonistas de Receptores Adrenérgicos alfa 1/uso terapêutico
Idoso
Animais
Modelos Animais de Doenças
Cães
Avaliação Pré-Clínica de Medicamentos
Feminino
Seres Humanos
Indóis/uso terapêutico
Sintomas do Trato Urinário Inferior/etiologia
Sintomas do Trato Urinário Inferior/fisiopatologia
Masculino
Hiperplasia Prostática/complicações
Hiperplasia Prostática/patologia
Ratos
Ratos Sprague-Dawley
Testosterona/administração & dosagem
Micção/efeitos dos fármacos
Agentes Urológicos/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Adrenergic alpha-1 Receptor Antagonists); 0 (Indoles); 0 (Urological Agents); 3XMK78S47O (Testosterone); CUZ39LUY82 (silodosin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180120
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191469


  2 / 433 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:29385990
[Au] Autor:Schoendorfer N; Sharp N; Seipel T; Schauss AG; Ahuja KDK
[Ad] Endereço:School of Medicine, University of Queensland, Herston, Australia.
[Ti] Título:Urox containing concentrated extracts of Crataeva nurvala stem bark, Equisetum arvense stem and Lindera aggregata root, in the treatment of symptoms of overactive bladder and urinary incontinence: a phase 2, randomised, double-blind placebo controlled trial.
[So] Source:BMC Complement Altern Med;18(1):42, 2018 Jan 31.
[Is] ISSN:1472-6882
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Storage lower urinary tract symptoms (LUTS) including overactive bladder (OAB) and urinary incontinence (UI) affect millions of people worldwide, significantly impacting quality of life. Plant based medicines have been documented both empirically and in emerging scientific research to have varying benefits in reducing bladder symptoms. We assessed the efficacy of Urox®, a proprietary combination of phytomedicine extracts including, Cratevox™ (Crataeva nurvala) stem bark, Equisetem arvense stem and Lindera aggregata root, in reducing symptoms of OAB and UI. METHODS: Efficacy of the herbal combination on a variety of bladder symptoms compared to an identical placebo, were documented in a randomised, double-blind, placebo controlled trial conducted at two primary care centres. Data were collected at baseline, 2, 4 and 8 weeks, with the primary outcome being self-reported urinary frequency. Statistical analysis included mixed effects ordered logistic regression with post hoc Holm's test to account for repeated measures, and included an intention-to-treat analysis. RESULTS: One hundred and fifty participants (59% female, aged; mean ± SD; 63.5 ± 13.1 years) took part in the study. At week 8, urinary day frequency was significantly lower (OR 0.01; 95%CI 0.01 to 0.02; p < 0.001) in response to treatment (mean ± SD; 7.69 ± 2.15/day) compared to placebo (10.95 ± 2.47/day). Similarly, episodes of nocturia were significantly fewer (OR 0.03; 95%CI 0.02 to 0.05) after 8 weeks of treatment (2.16 ± 1.49/night) versus placebo (3.14 ± 1.36/night). Symptoms of urgency (OR 0.02; 95%CI 0.01 to 0.03), and total incontinence (OR 0.03; 95% CI 0.01 to 0.06) were also lower (all p < 0.01) in the treatment group. Significant improvements in quality of life were reported after treatment in comparison to placebo. No significant side effects were observed resulting in withdrawal from treatment. CONCLUSIONS: The outcome of this study demonstrated both statistical significance and clinical relevance in reducing symptoms of OAB, urinary frequency and/or urgency and incontinence. The demonstrated viability of the herbal combination to serve as an effective treatment, with minimal side-effects, warrants further longer term research and consideration by clinicians. TRIAL REGISTRATION: NCT02396160 (registered on 17 March 2015 - before any statistical analyses commenced).
[Mh] Termos MeSH primário: Extratos Vegetais/uso terapêutico
Bexiga Urinária Hiperativa/tratamento farmacológico
Incontinência Urinária/tratamento farmacológico
Agentes Urológicos/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Capparaceae
Equisetum
Feminino
Seres Humanos
Lindera
Masculino
Registros Médicos
Meia-Idade
Fitoterapia
Extratos Vegetais/farmacologia
Micção/efeitos dos fármacos
Agentes Urológicos/farmacologia
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Plant Extracts); 0 (Urological Agents)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180202
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1186/s12906-018-2101-4


  3 / 433 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29465566
[Au] Autor:Zhao Y; Zhou J; Mo Q; Wang Y; Yu J; Liu Z
[Ad] Endereço:Department of Acupuncture, Guang'anmen Hospital, China Academy of Chinese Medical Sciences.
[Ti] Título:Acupuncture for adults with overactive bladder: A systematic review and meta-analysis of randomized controlled trials.
[So] Source:Medicine (Baltimore);97(8):e9838, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Overactive bladder is stated as the occurrence of urinary urgency which will cause negative impacts and decrease patients' health-related quality of life. The aim of this systematic review is to assess the efficiency and safety of acupuncture for adults with overactive bladder (OAB) comparing with sham-acupuncture, drugs, and acupuncture plus drugs. METHODS: We independently searched 9 databases from beginning to August 15, 2017. Two writers extracted data at the same time independently. Study outcomes were calculated by standardized mean differences (SMD) with 95% confidence intervals (CIs) and mean difference (MD) with 95% CIs. RESULTS: Ten randomized controlled trials (RCTs) with 794 patients were included in this systematic review. The combined results showed that electroacupuncture (EA) may be more effective than sham electroacupuncture (sham EA) in improving the 24-hour nocturia episodes and EA may enhance tolterodine for relieving voiding symptoms and enhancing patients' quality of life. However, more trials with high quality and larger sample sizes will be needed in the future to provide sufficient evidence. Only 15 of 794 OAB patients from the included studies reported mild adverse reactions related to EA, therefore, acupuncture is safe for treating OAB. CONCLUSION: Acupuncture might have effect in decreasing the number of micturition episodes, incontinence episodes, and nocturia episodes. However, the evidence is insufficient to show the effect using acupuncture alone or the additional effect to drugs in treating OAB.
[Mh] Termos MeSH primário: Terapia por Acupuntura
Bexiga Urinária Hiperativa/terapia
[Mh] Termos MeSH secundário: Terapia por Acupuntura/efeitos adversos
Adulto
Seres Humanos
Bexiga Urinária Hiperativa/tratamento farmacológico
Bexiga Urinária Hiperativa/fisiopatologia
Micção
Agentes Urológicos/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Urological Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180222
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009838


  4 / 433 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28889761
[Au] Autor:Araklitis G; Cardozo L
[Ad] Endereço:a Department of Urogynaecology , King's College Hospital , London , UK.
[Ti] Título:Safety issues associated with using medication to treat overactive bladder.
[So] Source:Expert Opin Drug Saf;16(11):1273-1280, 2017 Nov.
[Is] ISSN:1744-764X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The mainstay of overactive bladder treatment is the use of anticholinergic medication with its common side effects well known. This review focused on three less well-known safety issues when treating OAB. Areas covered: Patients with increased anticholinergic load are at risk of cognitive decline, dementia or even death. The elderly are particularly at risk due to polypharmacy. Botulinum toxin carries the risk of high urinary residuals, urinary tract infection and need to self catheterise. The use of vaginal oestrogens may improve OAB symptoms, but there is concern in those with a history of breast cancer. Studies have shown that the systemic absorption is negligible and does not increase the risk of recurrence. Expert Opinion: Improvement in assessing anticholinergic load is needed with the development of a universal drug scale. To avoid increasing load, Mirabegron or botulinum toxin can be used instead. There is no consensus of the use of prophylactic antibiotics when injecting botulinum toxin and at what residual to initiate self catheterisation. Despite evidence showing that the use of vaginal oestrogens is safe in those with a history of cancer, it is not fully supported by any health body. Further work is needed in those using aromatase inhibitors.
[Mh] Termos MeSH primário: Antagonistas Colinérgicos/efeitos adversos
Bexiga Urinária Hiperativa/tratamento farmacológico
Agentes Urológicos/efeitos adversos
[Mh] Termos MeSH secundário: Acetanilidas/administração & dosagem
Acetanilidas/efeitos adversos
Idoso
Toxinas Botulínicas/administração & dosagem
Toxinas Botulínicas/efeitos adversos
Antagonistas Colinérgicos/administração & dosagem
Estrogênios/administração & dosagem
Estrogênios/efeitos adversos
Seres Humanos
Polimedicação
Tiazóis/administração & dosagem
Tiazóis/efeitos adversos
Agentes Urológicos/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Acetanilides); 0 (Cholinergic Antagonists); 0 (Estrogens); 0 (Thiazoles); 0 (Urological Agents); EC 3.4.24.69 (Botulinum Toxins); MVR3JL3B2V (mirabegron)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170912
[St] Status:MEDLINE
[do] DOI:10.1080/14740338.2017.1376646


  5 / 433 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28603113
[Au] Autor:Ullah N; Khan MA; Khan S; Roohullah -; Khan A; Ahmad W
[Ad] Endereço:Department of Pharmacy, University of Swabi, Swabi, KPK, Pakistan.
[Ti] Título:Nephroprotective property of Cinnamomum zeylanicum and its antibacterial activity in combination with gantamicin.
[So] Source:Pak J Pharm Sci;30(1):55-60, 2017 Jan.
[Is] ISSN:1011-601X
[Cp] País de publicação:Pakistan
[La] Idioma:eng
[Ab] Resumo:Cinnamomum zeylanicum has strong antioxidant properties and has been presented to have nephroprotective effects. Present work was aimed to study the nephroprotective property of the plant extract through urinary enzymes excretion, to confirm its protective effects and to observe the antibacterial activities of gentamicin in combination with the plant extract. 200mg/kg/day of the plant extracts were administered alone and as co-therapy with gentamicin. Urinary lactate dehydrogenase (LDH) and Urinary alkaline phospatase (ALP) excretions were observed through reagents kits with the help of Power-Lab 300. Antibacterial activities were assessed for gentamicin alone and in combination with the extract. Present study showed that the plant extract have excess quantity of flavonoids, which may responsible for attenuating the excessive excretion of urinary LDH. However, Urinary ALP excretion was found remained same throughout the study period in all experimental groups; might be detected in acute damage. Further, the plant also proved to have no decreasing impact on the antibacterial activities of gentamicin.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Bactérias/efeitos dos fármacos
Cinnamomum zeylanicum/química
Gentamicinas/farmacologia
Rim/efeitos dos fármacos
Compostos Fitoquímicos/farmacologia
Agentes Urológicos/farmacologia
[Mh] Termos MeSH secundário: Fosfatase Alcalina/urina
Animais
Antibacterianos/isolamento & purificação
Bactérias/crescimento & desenvolvimento
Citoproteção
Testes de Sensibilidade a Antimicrobianos por Disco-Difusão
Quimioterapia Combinada
Rim/enzimologia
L-Lactato Desidrogenase/urina
Compostos Fitoquímicos/isolamento & purificação
Fitoterapia
Plantas Medicinais
Coelhos
Agentes Urológicos/isolamento & purificação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Gentamicins); 0 (Phytochemicals); 0 (Urological Agents); EC 1.1.1.27 (L-Lactate Dehydrogenase); EC 3.1.3.1 (Alkaline Phosphatase)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170613
[St] Status:MEDLINE


  6 / 433 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28444714
[Au] Autor:Badawi JK; Bosch R; Djurhuus JC; Hanna-Mitchell AT
[Ad] Endereço:Department of Urology, University Hospital Mannheim, Medical Faculty of the Ruprechts-Karls-University of Heidelberg, Mannheim, Germany.
[Ti] Título:Is testosterone important in LUT function in men and women? ICI-RS 2015.
[So] Source:Neurourol Urodyn;36(4):859-862, 2017 04.
[Is] ISSN:1520-6777
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:AIM: This review article is a collaborative report based upon the Authors' presentations and Group discussion on the role of testosterone (T) in the male and female lower urinary tract (LUT) which took place at the 6th International Consultation on Incontinence Research Society's (ICI-RS) annual meeting, in Bristol, UK (September 8-10, 2015). METHODS: It comprises overviews and opinions on both the current state of knowledge of the role of T in LUT function and dysfunction in both sexes. RESULTS: Results from animal studies suggest that T treatment may be beneficial for disorders of the LUT in women including urinary incontinence and pelvic organ prolapse. The need for clinical studies to evaluate the effect of T treatment in peri- and post-menopausal women, taking into account the type of applied androgen, the application form, timing and dosage, is especially emphasized. In males, findings on the impact of T on the male external urethral sphincter underscores that there is still much to learn about its role in male LUT physiology. The important topic of the use of T therapy in the treatment of enuresis in the young, both sexes, is also discussed. The importance of understanding the steroidogenic pathways linking T with estradiol is discussed as being of paramount importance in researching the unique actions of T in the LUT. CONCLUSION: The overall conclusion is that further research into the role of T in LUT function and dysfunction across genders and age groups (young to old) is extremely important. Neurourol. Urodynam. 36:859-862, 2017. © 2017 Wiley Periodicals, Inc.
[Mh] Termos MeSH primário: Sintomas do Trato Urinário Inferior/fisiopatologia
Testosterona/metabolismo
Fenômenos Fisiológicos do Sistema Urinário/efeitos dos fármacos
Sistema Urinário/efeitos dos fármacos
Sistema Urinário/fisiopatologia
[Mh] Termos MeSH secundário: Animais
Feminino
Seres Humanos
Masculino
Testosterona/administração & dosagem
Testosterona/sangue
Agentes Urológicos/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Urological Agents); 3XMK78S47O (Testosterone)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171121
[Lr] Data última revisão:
171121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170427
[St] Status:MEDLINE
[do] DOI:10.1002/nau.23041


  7 / 433 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28444708
[Au] Autor:Apostolidis A; Averbeck MA; Sahai A; Rahnama'i MS; Anding R; Robinson D; Gravas S; Dmochowski R
[Ad] Endereço:2nd Department of Urology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
[Ti] Título:Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015).
[So] Source:Neurourol Urodyn;36(4):882-893, 2017 04.
[Is] ISSN:1520-6777
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:AIMS: To review and assess the definitions of drug resistance and the evidence supporting treatment for drug resistant overactive bladder/detrusor overactivity (OAB/DO). METHODS: Evidence review of the extant literature and consensus of opinion was used to derive the summary recommendations. RESULTS: Drug resistance or drug refractory status has been inconsistently defined and reported in current evident sources. Recent publications use some correlation of lack of efficacy and or experienced side effects to define drug resistance. Algorithms based upon these definitions largely relate to the appropriate use of neuromodulation or botulinum neurotoxin, based upon patient selection and patient choice. Current treatment pathways are hampered by inability to consistently profile patients to optimize management, particularly after failure of initial pragmatic treatment. CONCLUSIONS: Further research is recommended to better identify patient phenotype for purposes of directing optimized therapy for OAB/DO. Current treatment algorithms are influenced by extensive data generated from recent neuromodulation and botulinum neurotoxin trials.
[Mh] Termos MeSH primário: Algoritmos
Resistência a Medicamentos
Bexiga Urinária Hiperativa/tratamento farmacológico
[Mh] Termos MeSH secundário: Seres Humanos
Bexiga Urinária/efeitos dos fármacos
Bexiga Urinária Hiperativa/fisiopatologia
Bexiga Urinária Hiperativa/cirurgia
Urodinâmica/efeitos dos fármacos
Agentes Urológicos/farmacologia
Agentes Urológicos/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Urological Agents)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171121
[Lr] Data última revisão:
171121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170427
[St] Status:MEDLINE
[do] DOI:10.1002/nau.23170


  8 / 433 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28394493
[Au] Autor:Sugiyama R; Aizawa N; Ito H; Fujimura T; Suzuki M; Nakagawa T; Fukuhara H; Kume H; Homma Y; Igawa Y
[Ad] Endereço:Department of Continence Medicine, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.
[Ti] Título:Synergic Suppressive Effect of Silodosin and Imidafenacin on Non-Voiding Bladder Contractions in Male Rats with Subacute Bladder Outlet Obstruction.
[So] Source:Low Urin Tract Symptoms;9(2):94-101, 2017 May.
[Is] ISSN:1757-5672
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To investigate single or combined effect of silodosin, an α1A-adrenoceptor antagonist, and imidafenacin, an antimuscarinic agent, on bladder function in a subacute bladder outlet obstruction (BOO) model of male rats. METHODS: Partial BOO was created in male Wistar rats by ligating the urethra with a steel rod. On day 10 after surgery, when frequent voiding was most remarkable on voiding behavior measurement in a metabolic cage, cystometric investigations in a conscious restrained condition were conducted with cumulative intravenous administration of silodosin alone (0.1, 1, 10, and 100 µg/kg), imidafenacin alone (1, 3, and 10 µg/kg), or a combination of the two drugs. RESULTS: When compared with the Sham rats, the BOO rats showed an increase in bladder capacity, residual volume, mean amplitude and the number of non-voiding contractions (NVCs), accompanied with an increase in bladder weight. In the BOO rats, silodosin alone at 100 µg/kg significantly decreased the number of NVCs, whereas imidafenacin alone at 3 and 10 µg/kg significantly decreased both the number and mean amplitude of NVCs. The combination administration with lower doses (silodosin at 10 µg/kg and imidafenacin at 1 µg/kg) significantly suppressed both the number and mean amplitude of NVCs. CONCLUSIONS: The present results indicate a suppressive effect of silodosin or imidafenacin alone and a synergic effect of the combination of these two drugs on NVCs in a subacute BOO model of male rats.
[Mh] Termos MeSH primário: Imidazóis/farmacocinética
Indóis/farmacologia
Antagonistas Muscarínicos/farmacologia
Contração Muscular/efeitos dos fármacos
Obstrução do Colo da Bexiga Urinária/tratamento farmacológico
Agentes Urológicos/farmacologia
[Mh] Termos MeSH secundário: Doença Aguda
Animais
Modelos Animais de Doenças
Combinação de Medicamentos
Masculino
Tamanho do Órgão
Ratos Wistar
Bexiga Urinária/efeitos dos fármacos
Bexiga Urinária/patologia
Obstrução do Colo da Bexiga Urinária/patologia
Micção/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Combinations); 0 (Imidazoles); 0 (Indoles); 0 (Muscarinic Antagonists); 0 (Urological Agents); CUZ39LUY82 (silodosin); XJR8Y07LJO (imidafenacin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170918
[Lr] Data última revisão:
170918
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170411
[St] Status:MEDLINE
[do] DOI:10.1111/luts.12109


  9 / 433 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28379598
[Au] Autor:Graziano S; Montana A; Zaami S; Rotolo MC; Minutillo A; Busardò FP; Marinelli E
[Ad] Endereço:Drug Abuse and Doping Unit, Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy. fra.busardo@libero.it.
[Ti] Título:Sildenafil-associated hepatoxicity: a review of the literature.
[So] Source:Eur Rev Med Pharmacol Sci;21(1 Suppl):17-22, 2017 Mar.
[Is] ISSN:2284-0729
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:Sildenafil citrate (Viagra®) is a vasoactive agent available worldwide since 1998 for the treatment of male erectile dysfunction. It is a selective phosphodiesterase type 5-enzyme inhibitor able to potentiate the downstream effects of nitric oxide on smooth muscle relaxation and vasodilation through its effects on the cyclic guanosine monophosphate (c-GMP) pathway in the erectile tissue of the penis. When sildenafil is orally administered, it is rapidly absorbed with a maximum plasma concentration achieved within 1 h and has a terminal half-life of between 3 to 6 h. The drug is extensively and rapidly metabolized by the liver, primarily by the CYP3A4 enzyme. Although the drug is well tolerated, specific adverse events have been observed, like flushing, headaches, dyspepsia, and visual disturbances. Liver toxicity related to sildenafil consumption has been considered a very rare event. However, in the last decade, some cases of sildenafil-associated hepatotoxicity have been reported. Furthermore, some hepatic intoxications have been reported after the intake of "natural" or "herbal" aphrodisiac supplements sold through Internet, sex shops, social media, and by word-of-mouth found to contain sildenafil and other phosphodiesterase type 5 (PDE-5) inhibitors. Studies investigating a possible link between sildenafil use and liver damage are limited, and the underlying mechanism responsible for hepatotoxicity is still missing. Studies in animals evidence that the hematopoietic function of the liver may have severely been affected as a result of a probable toxic effect of sildenafil. Here, the studies reporting liver toxicity by sildenafil in humans and in animals are reported and discussed.
[Mh] Termos MeSH primário: Doença Hepática Induzida por Substâncias e Drogas
Citrato de Sildenafila/efeitos adversos
Sulfonas/uso terapêutico
Agentes Urológicos/efeitos adversos
[Mh] Termos MeSH secundário: Disfunção Erétil/tratamento farmacológico
Seres Humanos
Masculino
Piperazinas/uso terapêutico
Purinas/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Piperazines); 0 (Purines); 0 (Sulfones); 0 (Urological Agents); BW9B0ZE037 (Sildenafil Citrate)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170726
[Lr] Data última revisão:
170726
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170406
[St] Status:MEDLINE


  10 / 433 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28371019
[Au] Autor:Sussman D; Yehoshua A; Kowalski J; Lee W; Kish J; Chaudhari S; Murray B
[Ad] Endereço:Division of Urology, Department of Surgery, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA.
[Ti] Título:Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis.
[So] Source:Int J Clin Pract;71(3-4), 2017 Mar.
[Is] ISSN:1742-1241
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Adherence and persistence rates of anticholinergic (ACH) therapies have been well described. To date, few studies describe these metrics for mirabegron in patients with overactive bladder. METHODS: This retrospective analysis of MarketScan database assessed adherence and persistence of patients receiving either mirabegron or ACH. Study eligibility required an index date (first prescription filled) between July 2012 and June 2013 with 12 months of continuous enrolment preindex date and 12 months of follow-up. Adherence was defined as a proportion of days covered of ≥ 80% among patients with at least 2 fills of index medication. Persistence measures included treatment failure described as either treatment discontinuation (medication supply gap ≥ 30 days) or switching to a different medication. A medication supply gap of ≥ 45 days was used as a sensitivity analysis. RESULTS: The mean age of mirabegron users (n = 4037) was 67 years and 43% were ACH naïve while the mean age of ACH users was 62 years (n = 67,943). Over the 12-month follow-up period, 44% of patients treated with mirabegron and 31% of patients treated with ACH were adherent to their indexed medications. Treatment failure was 81% for mirabegron and 88% for ACH. Most mirabegron treatment failures were because of treatment discontinuation (67%) versus switching to ACH therapy (14%). The ACH discontinuation rate was 84% and treatment switching rate was 4%. The mean (standard deviation) time to treatment failure was 143 (130) days for mirabegron and 69 (69) days for ACH. Adherence and persistence patterns were similar in the sensitivity analysis using a ≥ 45-day supply gap threshold. CONCLUSIONS: This real-world study demonstrated low adherence and persistence to mirabegron similar to ACH therapies.
[Mh] Termos MeSH primário: Acetanilidas/uso terapêutico
Antagonistas Colinérgicos/uso terapêutico
Cooperação do Paciente/estatística & dados numéricos
Tiazóis/uso terapêutico
Bexiga Urinária Hiperativa/tratamento farmacológico
Agentes Urológicos/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Bases de Dados Factuais
Preparações de Ação Retardada
Feminino
Seres Humanos
Masculino
Meia-Idade
Estudos Retrospectivos
Recusa do Paciente ao Tratamento/estatística & dados numéricos
Bexiga Urinária Hiperativa/prevenção & controle
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Acetanilides); 0 (Cholinergic Antagonists); 0 (Delayed-Action Preparations); 0 (Thiazoles); 0 (Urological Agents); MVR3JL3B2V (mirabegron)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170529
[Lr] Data última revisão:
170529
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170404
[St] Status:MEDLINE
[do] DOI:10.1111/ijcp.12824



página 1 de 44 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde